Genetic Triglyceride Disorders & Clinical Impact of PCSK9 Inhibition Evidence: Highlights from the National Lipid Association’s Clinical Lipid Update

2.00 CME
1.90 CNE
120 MINS
$0 FEE
SAVE
Cardiology Activity

TARGET AUDIENCE
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, and advance practice registered nurses with an interest in lipid management. 

TYPE OF ACTIVITY 
Internet Enduring Activity; Knowledge 

EDUCATIONIAL OBJECTIVES
At the conclusion of this activity, all participants should be able to:

  • Assess the implications of recent ASCVD outcomes data for the clinical management of patients with dyslipidemia. 
  • Identify genetic triglyceride disorders, including Familial Combined Hyperlipidemia, Hypertriglyceridemia and Familial Chylomicronemia Syndrome (FCS), in clinical practice.
  • Review current management recommendations and emerging therapeutic interventions for improving the outcomes in patients with FCS.
  • Implement a team-based approach to the clinical management of FCS, effectively involving lipidologists, gastroenterologists, nurses, pharmacists, dietitians, lifestyle educators and other healthcare professionals.

CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s participation in the activity and post-assessment with a score of 75% or greater and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit. A statement of credit will be available upon completion of an online evaluation/claimed credit form at www.lipid.org/cme. The deadline to claim credit is July 8, 2020.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

For any questions regarding credit please contact cme@lipid.org

COMMERCIAL SUPPORT
This activity is supported by educational funding provided by Akcea Therapeutics and Amgen.

CREDIT DESIGNATION 

CME/CE credit provided by the National Lipid Association 

In support of improving patient care, The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Pharmacist Accreditation Statement
Universal Activity Number JA0007192-0000-19-021-H01-P (Application)
This Activity has been approved for 2.00 contact hour(s) (.20 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
The maximum number of hours awarded for this CE activity is 1.9 contact hours.

DISCLOSURE INFORMATION
Lori A. Alexander, MSHS, RD, CLS, FNLA
Has nothing to disclose.

Christopher P. Cannon, MD
Consultant: Alnylam, Amarin, Amgen, Arisaph, Astra Zeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eisai, GlaxoSmithKline, Kowa, Lipimedix, Merck, Pfizer, Regeneron, Sanofi, Takeda
Contracted Research: Amgen, Arisaph, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, Merck, Takeda

Kellie H. McLain, ANP-BC, CLS
Has nothing to disclose

Joseph J. Saseen, PharmD, CLS, FNLA
Has nothing to disclose.

Vikesh K. Singh, MD, MSc
Advisory Board: Ariel Predicision Medicine
Consultant: AbbVie, Akcea

Daniel E. Soffer, MD, FNLA
Advisory Board: Akcea
Contracted Research: Akcea, Amgen, AstraZeneca, Esperion, Ionis Pharmaceuticals, Kowa, Novartis, Sanofi, Regeneron, Regenex
Speakers Bureau: Sanofi

Staff Disclosures
NLA Staff 
Has nothing to disclose. 

NLA CME Committee Reviewers
Khalid Hasan Sheikh, MD, FNLA 

Speaker: Amarin, Amgen, Novartis

Scott W. Shurmur, MD, FNLA 
Speaker: Regeneron

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.  

DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.